Table 4.
Regression: Probability of receipt of innovative therapy (oxaliplatin-containing regimen) among those receiving any chemotherapy, 2003–2006.
| Patient Characteristics | β | (SE) | p | OR | 95% CI |
|---|---|---|---|---|---|
| Gender (ref = Male) | |||||
| Female | −0.204 ** | (0.099) | 0.039 | 0.815 | (0.672 – 0.990) |
| Race (ref = Caucasian) | |||||
| African American | 0.240 | (0.211) | 0.256 | 1.272 | (0.840 – 1.925) |
| Other/Unknown | −0.033 | (0.234) | 0.887 | 0.967 | (0.611 – 1.530) |
| Age (ref = 65–69) | |||||
| 70–74 | −0.555 *** | (0.125) | <.001 | 0.574 | (0.450 – 0.733) |
| 75–79 | −0.939 *** | (0.121) | <.001 | 0.391 | (0.309 – 0.496) |
| 80–84 | −1.543 *** | (0.179) | <.001 | 0.214 | (0.151 – 0.303) |
| 85+ | −2.657 *** | (0.375) | <.001 | 0.070 | (0.034 – 0.146) |
| Education1 (ref=Quartile 1) | |||||
| Quartile 2: low-med education | 0.061 | (0.131) | 0.643 | 1.063 | (0.822 – 1.374) |
| Quartile 3: med-high education | −0.016 | (0.143) | 0.912 | 0.984 | (0.744 – 1.302) |
| Quartile 4: highest education | 0.342 ** | (0.152) | 0.025 | 1.408 | (1.045 – 1.898) |
| Primary site of tumor (ref=Cecum, ascending) | |||||
| Flexures, Transverse/Descending | −0.135 | (0.133) | 0.308 | 0.874 | (0.674 – 1.133) |
| Large intestine/NOS | −0.427 | (0.332) | 0.199 | 0.653 | (0.340 – 1.251) |
| Sigmoid | −0.094 | (0.121) | 0.434 | 0.910 | (0.718 – 1.153) |
| Tumor grade (ref=poorly differentiated) | |||||
| Well-differentiated | −0.402 | (0.270) | 0.136 | 0.669 | (0.395 – 1.135) |
| Moderately differentiated | −0.241 ** | (0.114) | 0.034 | 0.786 | (0.629 – 0.982) |
| Unknown | −0.103 | (0.284) | 0.718 | 0.903 | (0.517 – 1.576) |
| Year of Chemo (ref=2004) | |||||
| 2003 | −1.031 *** | (0.125) | <.001 | 0.357 | (0.279 – 0.455) |
| 2005 | 0.771 *** | (0.118) | <.001 | 2.162 | (1.715 – 2.725) |
| 2006 | 0.984 *** | (0.218) | <.001 | 2.675 | (1.745 – 4.101) |
| Dual eligibility (ref=no) | |||||
| Yes | −0.183 | (0.171) | 0.282 | 0.833 | (0.596 – 1.163) |
| Comorbidity conditions (ref=no, for each) | |||||
| Liver disease | 0.912 | (0.823) | 0.268 | 2.488 | (0.496 – 12.479) |
| Rheumatoid disease or AIDs | −0.136 | (0.558) | 0.808 | 0.873 | (0.293 – 2.606) |
| Renal disease | −1.887 ** | (0.746) | 0.012 | 0.152 | (0.035 – 0.655) |
| Dementia or paralysis | −0.371 | (0.678) | 0.585 | 0.690 | (0.183 – 2.608) |
| CHF or acute MI or CVD or COPD | −0.245 * | (0.129) | 0.058 | 0.782 | (0.607 – 1.008) |
| Neuropathy | −0.223 | (0.375) | 0.551 | 0.800 | (0.384 – 1.667) |
| Diabetes | −0.278 ** | (0.135) | 0.040 | 0.757 | (0.581 – 0.987) |
|
| |||||
| Organization characteristics (of treating hospital) | |||||
|
| |||||
| Proportion of claims from CCOP-affiliated MD or Hospital | 0.589 ** | (0.234) | 0.012 | 1.803 | (1.141 – 2.849) |
| Any Direct Cooperative group affiliation (ref=no) | 0.100 | (0.131) | 0.444 | 1.106 | (0.855 – 1.430) |
| Any Medical School Affiliation (ref=unaffiliated) | −0.132 | (0.149) | 0.376 | 0.877 | (0.655 – 1.173) |
| NCI -center affiliated (ref=no) | 0.627 | (0.884) | 0.478 | 1.873 | (0.331 – 10.592) |
|
| |||||
| Intercept | 0.571 *** | (0.212) | 0.007 | ||
|
| |||||
| Estimates of Model Fit | |||||
| QIC | 2592.84 | ||||
| QICu | 2585.32 | ||||
| Sample Size | 2,253 | ||||
Significance:
*
.10;
**
.05;
***
.01
1
Proportion of patient’s census tract population with high school education or greater.
-SEER regions were examined but are not reported.